comprehensive -WSS

comprehensive

author：explore 2025-09-27 12:57:23 - browse：1

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Latigo launches with $135 million for Vertex

WSS

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Trans patients at the end of life deserve respect and dignity

Abortion policy in the spotlight at Republican debate

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Intellia plays down concerns on accidental germline transmission

Hospital at home shows how to bring innovation to health care

hotspot

comprehensive

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Juul documents reveal insider tactics on political lobbying

How one medical school became remarkably diverse

California store owner shot dead in dispute over displaying Pride flag: Police

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

California store owner shot dead in dispute over displaying Pride flag: Police

Peter Hotez and the public health issue of online harassment

Tome Biosciences co

Psychedelics group wrestles with new pharma identity

Kellogg’s is going to war over Mexico’s nutrition label rules

leisure time

Long Covid research funding gets a major boost from NIH

Juul documents reveal insider tactics on political lobbying

Congress must protect the remaining independent doctors

People can get long Covid without testing positive for virus: Study

Congress considering partial increase for doctor pay in Medicare

Roche's accidental data boosts hopes for anti

focus

knowledge

entertainment

explore